• 产品名称Anti-EXOSC10抗体
    参阅全部 EXOSC10 一抗
  • 描述
    兔多克隆抗体to EXOSC10
  • 经测试应用适用于: WBmore details
  • 种属反应性
    与反应: Human
    预测可用于: Mouse, Rat, Rabbit, Horse, Guinea pig, Cow, Cat, Dog, Pig
  • 免疫原

    Synthetic peptide corresponding to a region within internal sequence amino acids 755-804 (ACKAAAEQAI SVRQQVVLEN AAKKRERATS DPRTTEQKQE KKRLKISKKP) of Human EXOSC10 (NP_001001998).

  • 阳性对照
    • Transfected 293T cell lysate



Our Abpromise guarantee covers the use of ab95028 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 101 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.


  • 功能Putative catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. EXOSC10 has 3'-5' exonuclease activity (By similarity). EXOSC10 is required for nucleolar localization of C1D and probably mediates the association of SKIV2L2, C1D and MPP6 wth the RNA exosome involved in the maturation of 5.8S rRNA.
  • 序列相似性Contains 1 3'-5' exonuclease domain.
    Contains 1 HRDC domain.
  • 细胞定位Cytoplasm. Nucleus, nucleolus. Nucleus. Strongly enriched in the nucleolus and a small amount has been found in cytoplasm supporting the existence of a nucleolar RNA exosome complex form.
  • Information by UniProt
  • 数据库链接
  • 别名
    • Autoantigen PM/Scl 2 antibody
    • Exosc10 antibody
    • Exosome component 10 antibody
    • EXOSX_HUMAN antibody
    • P100 polymyositis scleroderma overlap syndrome associated autoantigen antibody
    • P100 polymyositis-scleroderma overlap syndrome-associated autoantigen antibody
    • p2 antibody
    • p3 antibody
    • p4 antibody
    • PM Scl antibody
    • PM/Scl 100 antibody
    • PM/Scl-100 antibody
    • PMSCL antibody
    • PMSCL2 antibody
    • Polymyositis/scleroderma autoantigen 100 kDa antibody
    • Polymyositis/scleroderma autoantigen 2 100 kDa antibody
    • Polymyositis/scleroderma autoantigen 2 antibody
    • RRP6 antibody
    • Rrp6p antibody
    see all

Anti-EXOSC10 antibody 图像

  • Anti-EXOSC10 antibody (ab95028) at 1 µg/ml (in 5% skim milk / PBS buffer) + Transfected 293T cell lysate at 10 µg

    HRP conjugated anti-rabbit IgG at 1/50000 dilution

    Predicted band size : 101 kDa
  • Anti-EXOSC10 antibody (ab95028) at 1/1000 dilution + U2OS whole cell lysate at 100 µg

    Predicted band size : 101 kDa

    See Abreview

Anti-EXOSC10 antibody (ab95028)参考文献

ab95028 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (U2OS cells)
Loading amount 100 µg
Specification U2OS cells
Gel Running Conditions Reduced Denaturing (4-12% gradient gel)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C

Abcam user community

Verified customer

提交于 Jul 20 2012